Clinical trials for Pancreas cancer

154 currently recruiting clinical trials
Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT04585750 #2023-504251-27-00
Phase 2 autres tumeurs solides
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06898450
Parties A and B (Patients non sélectionnés)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Nimbus Wadjet, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT07213817 #2025-522139-33-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Ipsen
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 1 (Parties A, B, C, D) et module 2 (parties A et B) Tumeurs solides avancées
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Pancreas cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B6
Required histologic sub types
Adenocarcinoma Other
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06833008 #2024-519184-18-00
Required disease stage
Metastatic
Required genetic anomalies
Other KRAS BRAF KRAS G12C KRAS non G12C NRAS HRAS KRAS G12D
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Ipsen
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06819735
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Domain Therapeutics Australia Pty Ltd